Spinal muscle atrophy constitutes a major concern for healthcare providers. This rare genetic condition mainly affects children, weakening muscles, damage movement and other basic functions. Without early diagnosis and treatment, it is fatal in most cases. Serbia has made firm efforts to establish a national newborn screening plan for the devastation of the devastating influence of infants and their families to establish a national newborn screening plan.
Serbian scientists, together with Dr. Milošbrkušanin,, are used with Dr. Milošbrkušanin to be possible with doctors, patients, pharmaceutical companies, and decision makers. Serbian scientists make this inspiring story. They jointly resolved the challenge of SMA and ensured that every newborn in Serbia passed the test of this changing living conditions. Their work was introduced in detail in a study in the “International Newborn Screening Magazine”. This is a respected medical research platform.
Serbia’s plan uses a special technology to analyze DNA, and shortly after birth, the affected baby was determined. Early diagnosis can be treated in a timely manner, greatly improved results, and provided children with the best opportunity for healthy development. Dr. Brkuinanin said: “Our tasks are simple, but very powerful: found spinal muscle atrophy as soon as possible to achieve successful treatment.”
The study emphasizes how government support and partnerships ensure that all newborns can be tested, regardless of location or financial conditions. Dr. Brkuinanin added: “Our primary task is to ensure that every child can get early testing and treatment.” Scientists, doctors, pharmaceutical companies, and patient tissues have detailed plans. Models in other countries. Several babies diagnosed by this system have accepted the treatment of changing life, showing encouraging progress.
Dr. Savic-Pavicevic said: “This achievement marks the dawn of a new era in newborn screening, and uses genetic methods to bring hope to families that can be treated with SMA and other rare diseases.” Experts emphasize global cooperation and global cooperation and Sharing resources to solve the importance of health challenges together. The success of Serbia shows that how science is combined with the commitment to public hygiene can create extraordinary changes.
Through the establishment of this plan, Serbia not only provides a lifeline for the affected families, but also provides a powerful example, explaining the goals that can be achieved through pragmatic thoughts, determination and cooperation.
Journal reference
Brkuinaninm, Garai N, Karanovićj, etc. “From personal efforts to national support: newborn screening for newborn muscle atrophy in Serbia.” Int J newborn screen. 2024; 10 (3): 57. Doi: https: //doi.org/10.3390/ijns10030057
About the author
Milos Brkusanin It is a specialized researcher in the field of human molecular genetics. He pays special attention to genetic neuromuscular diseases. For more than a decade, his work has been centered on the core spinal cord atrophy (SMA) of his doctoral dissertation (SMA). In his research, Milos significantly promoted SMA’s molecular diagnostic procedures, thereby changing the diagnostic landscape of Serbia.
He also led a pioneering feasibility study to carry out newborns screening for SMA, paving the way for the plan he is currently supervised as the leader of the national newborn screening of Serbian national newborn SMA. In addition to diagnosis and screening, Milos also explores the potential of biomarkers to measure the effectiveness of SMA innovation gene therapy.
As an assistant professor at Belgrade University of Biology, he inspired the next generation of scientists and shared his professional knowledge as a highly sought -after speaker at the global conference. Milos Brkusanin’s work embodies the vision of innovation, dedication, and improving the ending of the patient.
Duaankasaviš-Pavićević He is a complete professor of molecular biology and the head of the Human Molecular Genetics Center of the School of Biology at the University of Belgra. Her long -term vision is to improve patient care by incorporating genetic testing into clinical practice. Through her dedicated efforts and the aggressive team’s commitment, more than 2,000 people in Serbia and neighboring countries were accurately diagnosed.
With the importance of early intervention after approval of SMA therapy, she determined that newborn screening is the next key milestone. Professor Savip-Pavićević supervised the feasibility study of SMA’s implementation of newborns screening, and currently supervise the Serbian national SMA newborn screening plan.
In addition to contributing to diagnosis and screening, she also serves as the main researcher of molecular genetic research in rare neuromuscular diseases. The focus is on muscle malnutrition, spinal muscle atrophy and muscle weakness. Her research aims to enhance her understanding of the mutation of individual patients to realize personalized treatment strategies and use the most advanced methods to identify novel biomarkers.
Nemanja Garai It is an emerging researcher at human molecular genetics who specializes in neuromuscular diseases. His work focuses on the genetic foundation of Gravis, which clarifies the genetic foundation and recognizes the weak immune muscle weakness, which is the central theme of his doctoral dissertation. Garai contributed to the pioneering feasibility study. This research has led to the establishment of newborns screening in Serbia, which plays a key role in the implementation of the national SMA screening plan that is underway. He assisted the project leader to organize the workflow to ensure the accuracy of the results of the newborn tested by each newborn and provide important support in daily operations.
As a teaching assistant of Berglaide University Biology Teachers, Garai combines his enthusiasm for research with his promise to teaching to guide the next generation of scientists. He also participated in the International Conference on Science and interacted with the global research community. Garai’s work examples have proved the practical application of science and improved the results of patients by integrating molecular genetics into the clinical environment.
